Meet Thought Leaders in Cancer Immunotherapy at the Premier Annual IO Event
As our understanding of tumor immunology has advanced, immuno-oncology has made unprecedented progress in improving the outcomes for cancer patients. Still, with the field in its infancy, the full curative potential of IO has yet to be realized. CHI’s 4th Annual Immuno-Oncology Summit has been designed to support a coordinated effort by industry players to bring commercial immunotherapies and immunotherapy combinations through clinical development and into the market. This weeklong, nine-meeting set will include topics ranging from early discovery through clinical development as well as emerging areas such as oncolytic virotherapy. Overall, this event will provide a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies.
Who Will Attend?
Scientific leaders, C-level executives, professors, site directors and researchers from pharma, biotech, academia, and government working in the areas of immuno-oncology, immunotherapy, antibody and protein engineering, biomarker discovery, immunology, cell and gene therapy, and preclinical and clinical development
Plenary Keynote Presentations:
A New Era of Personalized Therapy: Using Tumor Neoantigens to Unlock the Immune System
Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.
Neon Therapeutics, Inc. launched in 2015 to
focus on advancing neoantigen biology to improve
cancer patient care. A neoantigen-based
product engine will allow Neon to develop
further treatment modalities including next-generation
vaccines and T cell therapies targeting
both personalized as well as shared neoantigens.
The company’s first trial will launch later
this year investigating the combination of a
personalized, vaccine with nivolumab in advanced
Melanoma, NSCLC, and Bladder Cancer.
Emerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses
Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories
Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.
Reading Tea Leaves: The Dilemma of Prediction and Prognosis in Immunotherapy
Morganna Freeman, D.O., Medical Oncologist, Immunotherapeutics, The Angeles Clinic and Research Institute
With the rapid expansion of immunotherapeutics
in oncology, scientifically significant
advances have been made with both the depth
and duration of antitumor responses. However,
not all patients benefit, or quickly relapse, thus
much scientific inquiry has been devoted to
appropriate patient selection and how such
obstacles might be overcome. While more is
known about potential biomarkers, accurate
prognostication persists as a knowledge gap,
and efforts to bridge it will be discussed here.